Seton Hall University Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT03023540
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Seton Hall-Hackensack-Meridian School of Medicine, Hackensack, USA

Active Ingredients

Drugs in Phase 3 Trials (1)

pxt3003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Charcot-Marie-Tooth Disease (Phase 3)

Hereditary Sensory and Motor Neuropathy (Phase 3)

Nerve Compression Syndromes (Phase 3)

Tooth Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1